Sabiad, innovator in bacterial Imaging, secures investment from Pharma Connect Capital for pioneering work in Staphylococcus Aureus imaging

Sabiad, a groundbreaking start-up in Heerenveen, is pleased to announce that it has received significant investment support from Pharma Connect Capital (PCC). This funding will support the launch of their groundbreaking initiative. The project, in collaboration with the University Medical Center Groningen (UMCG), aims to develop an antibody for the detection and imaging of Staphylococcus aureus infections—a significant challenge, especially after orthopedic implantations such as hip and knee prostheses.

The bacterium Staphylococcus aureus, responsible for severe postoperative complications, presents symptoms that are often difficult to distinguish from normal immune reactions, leading to late diagnoses and delayed treatments with potentially serious consequences for patients.

Using an antibody invented by Professor Jan Maarten van Dijl (microbiologist) of the UMCG, rapid detection and visualization of the bacterium through bacterial imaging techniques can be achieved, enabling timely diagnostics and treatment. Sabiad is also working closely with Professor Paul Jutte (orthopedic surgeon), who will lead the first clinical study.

Jan Hendriks from Pharma Connect Capital explains: “Sabiad’s initiative and the contribution of UMCG align seamlessly with PCC’s mission. We are delighted to contribute to this next development phase emerging in the Northern Netherlands. The prospects for patients through the newly developed diagnostics are promising.”

Ton van den Hoven, co-founder of Sabiad, adds: “PCC’s investment is crucial for us. Their knowledge and extensive network are invaluable for the progress of early developments. Thanks to this funding, Sabiad can begin investigating the first patients in a research environment, allowing us to prepare for further clinical studies and product optimization for large-scale implementation.”

For additional information, please contact Ton van den Hoven at ton@sabiad.eu.

Photo: UMCG Research